Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers.

Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten.

Journal

Zeitschrift fur Gastroenterologie
ISSN: 1439-7803
Titre abrégé: Z Gastroenterol
Pays: Germany
ID NLM: 0033370

Informations de publication

Date de publication:
Oct 2020
Historique:
entrez: 9 10 2020
pubmed: 10 10 2020
medline: 21 10 2020
Statut: ppublish

Résumé

The COVID-19 pandemic is a global outbreak of new onset infections with the SARS-CoV-2 virus. To date, more than 3.4 million people have been infected throughout the world. In Germany, approximately 450,000 patients suffer from inflammatory bowel disease; these patients generally require continuous expert care and support. Against the background of a rapidly accumulating knowledge base on SARS-CoV-2, 68 expert authors of the current DGVS guidelines for Crohn's disease and ulcerative colitis took part in a virtual meeting to compile up-to-date, practice-orientated recommendations aimed at improving the care of patients with IBD. These recommendations address the risk of infection, including the risk for specific patient groups, the possible course of the disease, and consequences for pharmacological and surgical therapies of the underlying disease, as well as general measures for infection prevention and adjuvant prophylactic and therapeutic options.

Identifiants

pubmed: 33036052
doi: 10.1055/a-1234-8079
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

982-1002

Investigateurs

K Aden (K)
T Andus (T)
R Atreya (R)
F Autschbach (F)
O Bachmann (O)
D Bettenworth (D)
U Böcker (U)
B Bokemeyer (B)
T Brechmann (T)
P Bufler (P)
J Büning (J)
J Däbritz de Laffolie (J)
R Ehehalt (R)
Ph Esters (P)
K Fellermann (K)
St Fichtner-Feigl (S)
M Götz (M)
C Gross (C)
F Hartmann (F)
P Hartmann (P)
W Häuser (W)
K Herrlinger (K)
J C Hoffmann (JC)
S In der Smitten (S)
B Kaltz (B)
L Kanbach (L)
K Kannengießer (K)
K-M Keller (KM)
P Kienle (P)
J Klaus (J)
M Kreis (M)
A-J Kroesen (AJ)
W Kruis (W)
T Kühbacher (T)
J Langhorst (J)
L Leifeld (L)
A Lügering (A)
Ch Maaser (C)
H Matthes (H)
G Moog (G)
J H Niess (JH)
J Ockenga (J)
C Ott (C)
A Pace (A)
J Preiß (J)
M Reinshagen (M)
E Rijcken (E)
E Schnoy (E)
A Schreyer (A)
B Siegmund (B)
E F Stange (EF)
J Stein (J)
N Teich (N)
A Thomann (A)
Ch Treese (C)
C Veltkamp (C)
J Walldorf (J)
S Zeißig (S)
J Zemke (J)

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

For conflict of interest see: https://www.dgvs.de/wp-content/uploads/2020/07/ZfG-Leitlinie-Anhang-LL-CED-COVID_23.07.20.pdf

Auteurs

Andreas Stallmach (A)

Klinik für Innere Medizin IV (Gastroenterologie, Infektiologie und Hepatologie), Universitätsklinikum Jena, Jena.

Andreas Sturm (A)

Klinik für Innere Medizin, Schwerpunkt Gastroenterologie, DRK Kliniken Berlin | Westend, Berlin.

Irina Blumenstein (I)

Medizinische Klinik 1 (Gastroenterologie und Hepatologie, Pneumologie und Allergologie, Endokrinologie und Diabetologie sowie Ernährungsmedizin), Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt.

Ulf Helwig (U)

Internistische Praxengemeinschaft Oldenburg, Oldenburg.

Sibylle Koletzko (S)

Kinderklinik und Kinderpoliklinik im Dr. von Hauner Kinderspital, LMU Klinikum der Universität München, München.

Petra Lynen (P)

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselerkrankungen, Berlin.

Carsten Schmidt (C)

Medizinische Klinik II (Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Infektiologie), Klinikum Fulda, Universitätsmedizin Marburg - Campus Fulda, Fulda.

Axel Dignass (A)

Medizinische Klinik I, Agaplesion Markus Krankenhaus, Frankfurt.

Torsten Kucharzik (T)

Klinik für Innere Medizin, Gastroenterologie, Klinikum Lüneburg, Lüneburg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH